Analysis of refractory ascites components of patients with ovarian cancer, fallopian tube cancer and peritoneal cancer, and examination of influence by Cell-free and Concentrated Ascites Reinfusion Therapy (CART)

Analysis of refractory ascites components of patients with ovarian cancer, fallopian tube cancer and peritoneal cancer, and examination of influence by Cell-free and Concentrated Ascites Reinfusion Therapy (CART) - Analysis of ascites components, and examination of influence by CART

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034893

Enrollment

Registered

2018-11-19

Start date

2018-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer, fallopian tube cancer and peritoneal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients complicating refractory ascites with ovarian cancer, fallopian tube cancer and peritoneal cancer patients 2. Patients who are possible to puncture ascites 3. Patients who agree with the informed consent form 4. Patients aged from 20 to 79 years old at the time of obtaining informed consent 5. Patients who are necessary of CART

Exclusion criteria

Exclusion criteria: 1. Patients with fever and suspected of detecting endotoxin 2. Highly immunocompromised patients such as bone marrow transplantation 3. Patients with severe heart failure, renal failure, liver failure combined 4. Patients complicated with bacterial peritonitis 5. Serious liver disorder patients with overt jaundice 6. Patients used Bevacizumab within 6 weeks 7. Patients using steroids for mitigation purposes 8. Patients participating in other trials and clinical studies 9. Patients who are determined to be disqualified by a principal investigator

Design outcomes

Primary

Measure	Time frame
Cytokine profile of ascites, ascites after filtration and concentration, and serum.	—

Secondary

Measure	Time frame
A) Evaluation of QOL in pre-post CART B) Changes in cytokine levels of ascites filtered and concentrated ascites in storage at 4 degrees C) Blood test values of pre-post CART D) Adverse events	—

Countries

Japan

Contacts

Public ContactMasahiro Kagabu

Iwate Medical University School of Medicine Department of Obstetrics and Gynecology

mkagabu@iwate-med.ac.jp019-613-7111

Outcome results